Abstract
Purpose
The purpose of this study was to investigate the incidence of fosaprepitant-associated infusion site adverse events (ISAEs) among a cohort of breast cancer patients receiving doxorubicin/cyclophosphamide (AC) chemotherapy.
Methods
A retrospective review of electronic medical record (EMR) data was performed for all patients who were initiated on AC from January 2011 to April 2012. Data collected included baseline demographics, antiemetic regimen, documentation of ISAEs, and type of intravenous (IV) access. Descriptive statistics (mean and standard deviation or percentages) were summarized overall, by type of IV access and initial antiemetic given.
Results
Among the 148 patients included in this analysis, 98 initially received fosaprepitant and 44 received aprepitant. The incidence of ISAEs associated with fosaprepitant administration was 34.7 % (n = 34), while the incidence of aprepitant-associated ISAEs was 2.3 % (n = 1). All ISAEs were associated with peripheral IV access. The most commonly reported ISAEs were infusion site pain (n = 26), erythema (n = 22), swelling (n = 12), superficial thrombosis (n = 8), infusion site hives (n = 5), and phlebitis/thrombophlebitis (n = 5). Twenty-six patients experienced more than one type of ISAE.
Conclusions
The incidence and severity of ISAEs associated with fosaprepitant administration among a group of patients receiving AC chemotherapy are significant and appreciably higher than what has been previously reported.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rogers MP (2010) Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Clin J Oncol Nurs 14(4):5
Hesketh PJ (2011) Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). Support Care Cancer 19
Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104(7):1548–1555. doi:10.1002/cncr.21343
Herrington J (2008) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112
Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423–431. doi:10.1007/s00520-009-0680-9
Basch E (2011) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. J Clin Oncol 29(31)
Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol 29(11):1495–1501. doi:10.1200/JCO.2010.31.7859
Lasseter KC, Gambale J, Jin B, Bergman A, Constanzer M, Dru J, Han TH, Majumdar A, Evans JK, Murphy MG (2007) Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47(7):834–840. doi:10.1177/0091270007301800
EMEND (fosaprepitant dimeglumine) for Injection [package insert]. vol 2008. Merck & Co., Inc., Whitehouse Station, NJ
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381. doi:10.1016/j.jbi.2008.08.010
Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M, Eguchi K (2012) Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol. doi:10.1093/annonc/mds541
Fujii T, Nishimura N, Kanai H, Ishimaru H, Kawano J, Takahashi O, Yamauchi H, Yamauchi T Impact of fosaprepitant use on dermal and vascular adverse events in anthracycline-based regimens administered through peripheral lines. In: 2013 ASCO Annual Meeting, Chicago, IL, 2013.
Acknowledgments
This work was supported by the following United States National Institutes of Health Grant [CA124477 to C.L.L].
Conflict of interest
The authors have declared no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leal, A.D., Kadakia, K.C., Looker, S. et al. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer 22, 1313–1317 (2014). https://doi.org/10.1007/s00520-013-2089-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-013-2089-8